A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
← catalyst calendarNCT05983068 · readout in 253 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
48estimated
Sites
4
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-22 | actual | When the study began enrolling |
| Primary completion | 2027-04-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-19 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dermatitis Atopic
Intervention
- Drug: dupilumab — also filed as REGN668
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in TEWL after 5 STS assessed on lesional skin.
measured Baseline to Week 104
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed